Proove Biosciences
Home
Our History
Media
Contact
Proove Biosciences
Home
Our History
Media
Contact
More
  • Home
  • Our History
  • Media
  • Contact
  • Home
  • Our History
  • Media
  • Contact

The only lack of proof and outright fraud here was the misinformation that was uttered by a handful of disgruntled ex-employees and contractors, spread by the media, and perpetrated by some in the Southern District of California office of the U.S. Attorney and the FBI."


Brian Meshkin, Proove Founder

Announcement: Proove & its Founder Cleared of All Charges

“IN THE INTERESTS OF JUSTICE” BRIAN MESHKIN & PROOVE BIOSCIENCES CLEARED OF ALL CHARGES

“IN THE INTERESTS OF JUSTICE” BRIAN MESHKIN & PROOVE BIOSCIENCES CLEARED OF ALL CHARGES

“IN THE INTERESTS OF JUSTICE” BRIAN MESHKIN & PROOVE BIOSCIENCES CLEARED OF ALL CHARGES

U.S. Government Dismisses Case Against Proove Biosciences Founder and CEO Brian Meshkin.  False Charges Spread by STAT News Discarded.  Dismissal Issued as Leading Experts, Researchers, and Former Government Officials Prepared to Testify in Defense of Proove and Meshkin. 

PRESS RELEASE - PR Newswire - January 9, 2022 (Irvine, CA) – The U.S. District Court in the Central District of California has issued an order “in the interests of justice” granting a motion by the U.S. Department of Justice to dismiss all charges against all nine defendants named in United States of America vs. Brian Meshkin et al., clearing all parties of any wrongdoing. 


Founder and CEO Brian Meshkin of Proove Biosciences (“Proove”), along with four other employees and four physicians from the country’s largest pain management corporation, National Spine & Pain Center (“NSPC”), had been falsely accused of wrongdoing in connection with Proove, a then-highly successful personalized medicine corporation. About 30 days before trial, the U.S. government dismissed the case, in the face of mounting questions about prosecutorial misconduct, combined with a lack of credible evidence. This result is consistent with prior dismissals of two similar whistleblower lawsuits by disgruntled former employees based on false allegations. These false allegations levied against Meshkin and Proove caused tremendous harm, as they have been widely disseminated publicly and in the media. With this dismissal, the defendants are vindicated, and this flawed investigation has been thoroughly discredited. 


Meshkin’s legal defense team from Stradling, Yocca, Carlson & Rauth, led by Jason de Bretteville, put significant pressure on the government and were prepared to win at trial, in part through evidence establishing the legitimacy of Proove’s clinical research program and the lack of any criminal intent on the part of Meshkin. Defense witnesses included the former Secretary of the U.S. Department of Health and Human Services (and a Proove board member), leading physicians and researchers in the field of pain management, including former Presidents of the American Academy of Pain Medicine and American Society of Interventional Pain Physicians, former elected officials, former Proove employees, and more. That testimony and additional evidence establish Meshkin’s ethical and visionary leadership and the fact that Proove’s state-of-the-art precision medicine technology resulted in better patient outcomes, and is supported by award-winning research.


Meshkin reflected on the matter: “There has been so much injustice over the past 6 years that it is wonderful to see truth prevail. I am excited to have the opportunity to set the record straight and to move forward with my head held high.” 


While the government’s efforts eventually failed, Proove and Meshkin have paid the price for many years. On the heels of the 2021 indictment, the U.S. Attorney’s Office for the Southern District of California issued two press releases that contained blatantly false statements about the actions of Proove and the defendants, jeopardizing the defendants in the court of public opinion before the government had any credible evidence to support its claims. 


Throughout, Proove Executives and Directors maintained their innocence and took great pride in Proove’s innovative business, including: 


  • Proprietary Effective Technology: Predictive algorithms analyzing genetic and non-genetic factors in its CLIA-certified, CAP-accredited laboratory that helped doctors objectively assess pain, predict opioid misuse with up to 96.7% accuracy, and provide treatment insights which resulted in 50% pain reduction within 30 days of treatment changes, saving Medicare over $70 million annually.


  • Socially Responsible Billing: Billed Medicare at 50% of the fee schedule pricing compared to its competitors for similar lab tests.


  • Award-Winning Research: Conducted research consistent with international guidelines and U.S. laws, published 10 studies in peer-reviewed journals, presented over 140 posters at scientific meetings, and won awards from medical societies.


  • Ethical Business Practices: Provided employees paid health insurance and 40 hours of annual paid volunteer time; gender pay equality and a “majority-minority” company; a 10:1 ratio between CEO pay and the lowest paid employee; free testing for patients in need; an independent compliance hotline for employees to report concerns; and, an internal charity to help employees pay for personal financial challenges such as family funerals, childcare, and more.  



PROOVE FOUNDER BRIAN MESHKIN ISSUES A PERSONAL STATEMENT FOLLOWING THE DISMISSAL

“IN THE INTERESTS OF JUSTICE” BRIAN MESHKIN & PROOVE BIOSCIENCES CLEARED OF ALL CHARGES

“IN THE INTERESTS OF JUSTICE” BRIAN MESHKIN & PROOVE BIOSCIENCES CLEARED OF ALL CHARGES

“Those words used by the government to dismiss this case – “in the interests of justice” – ring especially true today for the millions affected by this misguided effort to destroy Proove. There has been so much injustice over the past 6 years that it is wonderful to see truth prevail. I am excited to have the opportunity to set the record straight and to move forward from here with my head held high. 


"You build a reputation over a life’s journey. Since I was a teenager, I’ve been blessed to initiate and be involved in efforts proven by U.S. government statistics to save tens of thousands of lives. Whether as a community activist, elected official, or entrepreneur, I’ve been on a mission to make the world a better place and I am grateful for what I have been able to achieve working together with many amazing and passionate people. 


"This controversy over the past six years was completely inconsistent with the previous 40 years of my life. It was personally and professionally traumatic, embarrassing, and unjust. This abuse was personally traumatic to my family – especially my three kids who had to deal with the embarrassment and financial destruction of their dad. It’s hard to put into words what it was like to go from having a stellar reputation and respected integrity for decades to then having to wear a ‘scarlet letter’ due to false, defamatory, and highly damaging “fake news” stories and irresponsible government actions that called into question my honesty and credibility. 


"Ultimately, the facts spoke for themselves. The Department of Justice moved to dismiss the baseless charges on their own motion and “in the interests of justice.” Proove was always about proof – hence the name. Could we predict what would work for a patient or who was at risk, and could we then track what happens to prove the accuracy of our prediction? This was at the heart of why I founded the Company at my dining room table in 2009 and led an amazing team of scientists, software developers, researchers, lab personnel and others for 8 years as we built a company that we were all very proud of. 


"This work was destroyed by misinformation spread by a handful of disgruntled ex-employees and contractors, spread by the media, and blindly adopted by some in the Southern District of California office of the U.S. Attorney and the FBI. That misinformation and false and defamatory allegations directed at Proove hurt thousands of people beyond the company itself, including the many patients and their families who have died from or whose lives were impacted by opioid overdoses and suicide that could have been prevented with access to Proove’s life-saving technology. It also was traumatic for the families of the hundreds of Proove employees who lost their jobs and incomes, and had their reputations called into question. These actions also harmed the thousands of doctors and dozens of hospitals who relied upon Proove testing to help their patients, including the good folks at National Spine & Pain Center. 


"Proove and the other defendants were victims of false reports that are easily disproven, but were spread by a few disgruntled ex-employees and recklessly published by STAT News writer, Charles Piller over multiple years. Piller, who now writes for Science, published by the American Association for the Advancement of Science, caused significant harm to all of us involved with Proove, exacerbating the false reports and baselessly drawing the attention of law enforcement. Along with other large genetic testing companies at the time, Proove received a subpoena in June 2017, and a governmental inquiry ensued. The inquiry was coordinated out of the United States Attorney’s office for the Southern District of California, led by Assistant U.S. Attorney Josh Green. Green, who had never prosecuted a healthcare fraud case before, and FBI Agent Leah Chambers, took an inexperienced, heavy-handed, and media-focused approach that resulted in Proove’s revenue dropping by 90% in 30 days due to the false media reports, and ultimately having to halt operations. While the government’s efforts eventually failed, Proove and me personally, have paid the price for many years. 


"In an attempt to “save face” after spending millions of taxpayer dollars and being unable to obtain any convictions or financial penalties for their efforts, the U.S. Attorney’s Office for the Southern District of California secured a plea agreement from a former sales distributor of Proove who was under investigation. In exchange for what turned out to be false information, the government agreed to ease the sales distributor’s sentence. Then, in the summer of 2021, NSPC, as a corporation, paid “walk away” money to the government to avoid costly litigation against the false allegations without any admission of wrongdoing. Thereafter, the Proove executives and NSPC doctors were indicted.


"As the founder and CEO of Proove, I have felt a tremendous personal burden due to the pain that this injustice caused so many people for whom I care about. Even though we have been vindicated – as the truth has finally prevailed “in the interests of justice” - I personally know that nothing can be done now to take away the pain that was caused, and the damage that was done because of these false allegations. For that, I am so sorry. I wish I could have prevented this. Just know that we are exploring ways to restore what was destroyed and I know many of our Proove team want to work together again.


"After the millions of lives harmed and millions of taxpayer dollars wasted in this foolish investigation, the government apparently can just say, “Oops, we are withdrawing and dismissing all charges.” Beyond how they purposefully smeared my reputation with false statements, they destroyed a company back in 2017 that was worth in excess of $200 million that provided a solution to our nation’s leading cause of preventable death, employed hundreds, and supported all of their families, earned millions in annual revenue and paid taxes, supported many other vendors and small businesses, helped many doctors and hospitals save patient lives or improve their conditions, and was preparing to IPO in 2017 to fund its mission to save lives and solve two epidemics – opioid overdoses and chronic pain. Instead of the good that could have been done over these past six years, these epidemics have just gotten worse: opioid overdoses have continued at a fast pace, and the chronic pain crisis has become 10% of all suicides in America. What do these specific government officials have to say in the face of this reality? Will they leverage the media now as they did at the time of the subpoena and indictments to address the damage done to my company, to me, and to all those involved, or just walk quietly away? 


"Having previously taken the oath to uphold the Constitution and laws of this great country and served as an elected official with distinction honoring that oath, I believe the actions of this Southern District of California prosecution team and these FBI agents – some of whom were disqualified due to not following procedures - are unfair to the many good public servants in government who serve our nation honorably. Also, I believe this sadly continues a trend of what we are seeing over the past several years where certain incidents raise questions about the government’s power. 

As for me, I am grateful for a loving and ever-present Heavenly Father, and for my Savior, Jesus Christ, who has helped me carry this heavy cross when I just didn’t have the strength. I am so proud of what we achieved at Proove Biosciences from 2009 until 2017, and I am so thankful that I can freely and publicly speak about this situation now to set the record straight and help others who face similar injustices. 


"I look forward to healing and rebuilding – personally and professionally. I am grateful to those family, friends, and colleagues who stood by me, told the truth and defended us. I am grateful for my legal team, my D&O insurance at Western World and AIG, and others who helped me navigate this traumatic situation. I know that we have had angels helping us every step of the way, as it is incredible to stand up with a little slingshot and win against the tidal wave of lies spread by irresponsible media outlets and the “giant” unlimited resources of the U.S. government. 


"I can’t think of a better gift during this holiday season, and I am hopeful for the new year.”

Media Coverage

Proove Founder Gets Federal Charges Dismissed

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

By Peter Brennan, Editor


"Brian Meshkin got his day in court, and he finally feels vindicated. U.S. District Court Judge Josephine Staton of the Central District of California on December 22 threw out all federal charges against Meshkin and five others."

Learn More

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

By Scott Schwebke, Investigator Reporter


The U.S. Attorney’s Office said in a court motion last week that it dismissed the case against Brian Javaade Meshkin, 46, “in the interests of justice.” The Ladera Ranch man, founder of Proove Biosciences Inc., was indicted in 2021 on charges of conspiracy and receiving and making illegal payments. 


The dismissal follows a Dec. 11 motion seeking an evidentiary hearing filed by Meshkin’s attorney, Jason de Bretteville.

The motion alleges a government “taint team” provided at least 85 potentially privileged documents belonging to Proove to prosecutors on the trial team.


“The court was made aware of what happened and they dismissed the case,” he said in a phone interview. “The prosecution’s investigation started in 2013 and, as a result, nine people were indicted. Then the prosecution walked quietly into the night 30 days before trial.”

Learn More

Proove Biosciences CEO Exonerated in PGx Test Kickback Case

Charges dropped against Irvine bioscience company founder in alleged kickback scheme

Proove Biosciences CEO Exonerated in PGx Test Kickback Case

By Jessica Cohen, Staff Reporter


A federal judge in California has dismissed charges against the CEO of embattled genetic testing company Proove Biosciences who along with other individuals had been accused of paying physicians at least $3.5 million in kickbacks.


In a statement published Monday, Proove said, "These false allegations levied against Meshkin and Proove caused tremendous harm, as they have been widely disseminated publicly and in the media. With this dismissal, the defendants are vindicated, and this flawed investigation has been thoroughly discredited."

Learn More

U.S. Government Soundly Defeated In Alleged Kickback Scheme

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

Proove Biosciences CEO Exonerated in PGx Test Kickback Case

By Kim Delmonico


The United States government was soundly defeated and forced to ask a Federal Judge to dismiss all charges against an innovative young California company and the clinics it serves.

The judge for the United States District Court in the Central District of California has issued an order granting the United States Government’s motion to dismiss all charges in a case involving physicians and other employees from Physical Medical Associates, Ltd., National Spine and Pain Center, LLC, and Proove Biosciences, Inc.


Proove is an Irvine, California-based biosciences company that specializes in the genetic testing of pain patients. According to the company, its “proprietary effective technology” includes “genetic tests and predictive software algorithms in its CLIA-certified, CAP-accredited state-of-the-art laboratory that helped doctors objectively assess pain, predict who would misuse opioids with up to 96.7% accuracy, and provide treatment insights which resulted in 50% pain reduction within 30 days of treatment changes, saving Medicare over $70 million annually.”

Learn More

Charges Against Founder of Genetic Testing Company Dropped

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

By Pat Anson, Editor


The U.S. Department of Justice has quietly dropped criminal charges against the founder and CEO of Proove Biosciences, a genetic testing company based in California that was accused of paying physicians over $3.5 million in illegal kickbacks. A judge dismissed the case against Brian Meshkin and five other defendants last month “in the interests of justice” after federal prosecutors declined to move forward with the case. 


“There has been so much injustice over the past 6 years that it is wonderful to see truth prevail.  I am excited to have the opportunity to set the record straight and to move forward from here with my head held high,” Meshkin said in a statement.

Learn More

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

San Diego feds dismiss fraud case amid accusations over prosecutorial missteps

By Alex Riggins


Jason de Bretteville, defense attorney for the lead defendant, Proove CEO Brian Meshkin, said the government attorneys never disclosed specifically why they sought a dismissal, but he speculated it was based on the case’s merits and “emerging issues relating to potential government misconduct.”


Meshkin said the decision to dismiss the case was vindication for him and his co-defendants.

“There has been so much injustice over the past (six) years that it is wonderful to see truth prevail,” Meshkin wrote in a statement he sent to the Union-Tribune. “Ultimately, the facts spoke for themselves.”

Meshkin called the investigation a “foolish” waste of millions of taxpayer dollars that resulted from “misinformation spread by a handful of disgruntled ex-employees and contractors, spread by the media, and blindly adopted by some in the Southern District of California office of the U.S. Attorney and the FBI.”

Learn More

Former Proove CEO Meshkin Starts Venture Fund: Plans lawsuits to fight “false allegations”

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

By Sherry Hseih, Healthcare Editor


Meshkin’s venture fund is a “social entrepreneurship accelerator that is helping profound social problems.” Profound Ventures plans to make seed investments in the five- to low six-digits, starting with healthcare opportunities. The current portfolio includes technologies to help people age at home.

Learn More

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

Brian Meshkin sought a way to help doctors make better decisions in the specialty of pain management, acting on the desire in 2009 when he created Irvine-based Proove Biosciences Inc. Meshkin, Proove’s founder and chief executive, was one of five winners honored by the Business Journal at its 15th annual Excellence in Entrepreneurship Awards at a March 10 luncheon at Hotel Irvine

Learn More

The genetic test that can help fix America’s opioid painkiller addiction

Proove CEO Wins Award at 15th Annual Excellence in Entrepreneurship Awards: He Felt Your Pain

The genetic test that can help fix America’s opioid painkiller addiction

By Jeniece Pettitt


Brian Meshkin founded Irvine, California-based Proove Biosciences in 2009. The company developed a portfolio of tests that can  determine  someone’s pain profile and tolerance to different pain  medications to  give doctors more information before prescribing  medication.

Learn More

A medical test that aims to wean America off painkillers

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

The genetic test that can help fix America’s opioid painkiller addiction

By Dina Gusovsky


Sixty percent of the score a patient receives is based on testing for genetic markets associated with addiction, of which there are  several, including COMT, dopamine receptors and the opioid MU1 receptor gene.

 The other 40 percent of the addiction-risk score comes from personal factors: age, personal medical history, previous substance abuse and any history of depression (due to its links to drug use). 

Learn More

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

An Irvine biotech company is hoping to take on the nation’s opioid epidemic with a genetic test it says can identify patients who are predisposed to getting addicted to painkillers.

The problem is clear: Nearly 2 million people were found to be addicted to pain medication and nearly 19,000 people died from taking pain medication in 2014, according to the American Society of Addiction Medicine.

Learn More

Doctor in the Dugout - Hoag Medicine (podcast)

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

Genetic Test Aims To Identify Those Predisposed To Opioid Addiction

Brian Meshkin is interviewed by Dr. Alan Beyer from Hoag Orthopedic Institute, a client of Proove Biosciences

Learn More

Videos

Proove Founder Brian Meshkin Speaks at Conference on Proove's Downfall in 2019

Brian Meshkin speaks at Medical Device Events Conference in 2019

Fmr Congressman Bono & Pain Genetics Expert Diatchenko Join CEO to Announce Data

Brian Meshkin is joined by Former Congresswoman Mary Bono and the Canada Excellence Chair of Pain Genetics Dr. Luda Diatchenko as Proove announces important data at the AAPM meeting in 2018

Proove CEO is the OCTANe Orange County CEO of the Year

Brian Meshkin is selected by the OCTANe/OC Tech Alliance as the CEO of the Year of an Emerging Technology Company

PRESS RELEASES

January 9, 2023: "IN THE INTERESTS OF JUSTICE" BRIAN MESHKIN AND PROOVE BIOSCIENCES CLEARED

U.S. Government Dismisses Case Against Proove Biosciences Founder and CEO Brian Meshkin.  False Charges Spread by STAT News Discarded.  Dismissal Issued as Leading Experts, Researchers, and Former Government Officials Prepared to Testify in Defense of Proove and Meshkin.

Click here

February 13, 2017: Clinical Utility Study Demonstrating Improved Patient Outcomes With Proove Pain P

Researchers from the University of Southern California, Interventional Pain Institute, and Proove Biosciences Publish Clinical Utility Study Supporting Precision Medicine in Pain Perception

Click here

December 12, 2016: Proove Biosciences Launches Version 2.0 of Its One-Of-A-Kind Proove P

World Leader in Precision Medicine Testing Incorporates Evidence-Based, Expert-Substantiated Clinical Phenotypes to Its Algorithm to Better Understand Patient Pain Sensitivity

Click here

December 7, 2016: Proove Biosciences Unveils First Precision Medicine Genetic Test for Painful TMJD

Proove Launches the Only Commercially Available Genetic Analysis Offering Personalized Medical Treatment Recommendations for TMD Sufferers and Insights Into Contributing Causes of Orofacial Pain

Click here

November 16, 2016: Proove Biosciences Ranked 69th Fastest Growing Company in North America

Listed on Deloitte Technology Fast500 - Attributes 1,386 Percent Revenue Growth to Successful Patented Precision Medicine Platform Designed to Improve Outcomes for Patients, Providers and Insurers

Click here

November 16, 2016: Proove Biosciences Ranked 69th Fastest Growing Company in North America

Listed on Deloitte Technology Fast500 - Attributes 1,386 Percent Revenue Growth to Successful Patented Precision Medicine Platform Designed to Improve Outcomes for Patients, Providers and Insurers

Click here

Press Release Archive

July 2016 - February 2017

July 2016 - February 2017

July 2016 - February 2017

Read about Proove's tremendous accomplishments from mid-2016 until early 2017

Click Here for Releases

2013 - summer 2016

July 2016 - February 2017

July 2016 - February 2017

Read about Proove's tremendous accomplishments from 2013 until the summer of 2016

Click here for releases

Connect With Us

Copyright © 2023 Proove Biosciences - All Rights Reserved.


This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept